Alvotech Inks $150M Licensing Deal with Lotus for Two Biosimilars

summarizeSummary

Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for two biosimilar candidates, with potential value of up to $150 million in upfront and milestone payments.

check_boxKey Events · M&A and Partnerships · ALVO

• Licensing Deal with Lotus

  Alvotech signed a semi-exclusive U.S. licensing and commercialization agreement with Lotus Pharmaceutical for AVT34 (durvalumab biosimilar) and AVT87 (emicizumab biosimilar).

• Up to $150M in Milestones

  The agreement has a potential value to Alvotech of up to approximately $150 million in upfront and milestone payments, plus ongoing revenues from product supply.

• First Direct U.S. Commercialization

  Alvotech retains the right to commercialize both products directly in the U.S. alongside Lotus, marking its first direct participation in U.S. commercialization.

• Asian Market Expansion

  Lotus receives exclusive commercialization rights in eight Asian markets: South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong, and Malaysia.

auto_awesomeAnalysis · ALVO · Life Sciences

A strategic licensing and commercialization agreement with Lotus Pharmaceutical covers two pipeline candidates: AVT34, a proposed biosimilar to Imfinzi (durvalumab), and AVT87, a proposed biosimilar to Hemlibra (emicizumab). The deal could be worth up to $150 million in upfront and milestone payments, plus ongoing supply revenues. Notably, this marks the first time Alvotech will participate directly in U.S. commercialization of its products—a meaningful shift in its commercial strategy. The agreement also grants Lotus exclusive rights in eight Asian markets, expanding Alvotech's reach. For a company with a market cap of approximately $1.7 billion, the deal is significant, especially after a period of heavy capital raises and recent financial losses, as it provides a non-dilutive source of potential future revenue.